Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cervarix 2-Dose vs 3-Dose Schedule Study
NCT01381575Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2011
- Primary completion
- Jun 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
A Phase 3 trial of Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen in human papillomavirus infection, sponsored by GSK. Started Jun 2011; status: completed.
02
Drugs
Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT01381575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01381575.